Exelixis, Inc. (EXEL) Insider Patrick J. Haley Sells 5000 Shares

Xavier Trudeau
Juin 6, 2017

Valuation Ratios of Exelixis, Inc. Following the completion of the sale, the director now owns 52,721 shares of the company's stock, valued at $1,137,719.18. Public Employees Retirement Association of Colorado's holdings in Exelixis were worth $932,000 at the end of the most recent quarter. Fortaleza Asset Management Inc. purchased a new stake in shares of Exelixis during the first quarter worth $106,000. Great West Life Assurance Co. Reiterates Hold on Exelixis (NASDAQ:EXEL) appeared first on Market Exclusive.

Shares of UnitedHealth Group Inc (NYSE:UNH) decreased -0.11% and closed at $179.39 after opening 179.92 with the overall traded volume of 2.61 million shares. Wells Fargo & Company MN boosted its stake in Exelixis by 167.1% in the first quarter. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in Exelixis by 237.5% in the first quarter.

Blair William & Company decreased Exelixis Inc (EXEL) stake by 7.25% reported in 2016Q4 SEC filing.

Investors and Traders continue to monitor technical levels of shares of Exelixis, Inc. Tracking most recent quarter period, Price to book (P/B) ration is at 1.54 and Price to cash per share ration is at 19.75. The market capitalization of the company is at $5.63 Billion. The stock is trading $20.98 its 50-day moving average by 1.94%.

Exelixis Incorporated (NASDAQ:EXEL) had an increase of 3.4% in short interest. The biotechnology company reported $0.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.06. The firm had revenue of $80.90 million for the quarter, compared to the consensus estimate of $65.23 million. The business's revenue for the quarter was up 425.3% compared to the same quarter past year. During the same period in the previous year, the business posted ($0.27) earnings per share. On average, equities analysts expect that Exelixis will post $0.18 earnings per share for the current fiscal year.

Simple Moving Averages trends about Exelixis, Inc. They use historic price data to observe stock price patterns to predict the direction of that price going forward. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & global copyright law. 232.36 million shares or 7.60% more from 215.94 million shares in 2016Q3 were reported. Finally, Zacks Investment Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Cann initiated coverage on shares of Exelixis in a research note on Wednesday, March 15th.

Needham & Company began new coverage on Exelixis, Inc. giving the company a " rating.

COPYRIGHT VIOLATION WARNING: "Exelixis' (EXEL) "Hold" Rating Reaffirmed at Oppenheimer Holdings Inc." was published by BBNS and is the sole property of of BBNS. Over the last three months, the shares of the company have changed -17.50% and performed 12.53% over the last six months. Legal & General Group Plc now owns 84,763 shares of the biotechnology company's stock worth $1,834,000 after buying an additional 1,078 shares in the last quarter. Also, insider Patrick J. Haley sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $21.98, for a total transaction of $879,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

In related news, insider Michael Morrissey sold 200,000 shares of the company's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $21.69, for a total value of $2,169,000.00. The disclosure for this sale can be found here.

Suncor Energy Inc. (SU) stock price tumbled -0.67% to close at $31.09 during recent trade. Corporate insiders own 5.90% of the company's stock. Brown Advisory Securities Limited Liability Company has 0.08% invested in Exelixis, Inc.

In 2017, Exelixis is focused on maximizing the opportunity for its two internally-discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer around the world.

D'autres rapports CampDesrEcrues

Discuter de cet article